Chronic hepatitis B: past, present, and future

Clinics in Liver Disease

Volumn 14, Issue 3, 2010, Pages 531-546

  Lai, Michelle ^a   Liaw, Yun Fan ^b  

^a HARVARD UNIVERSITY   (United States)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Hepatitis B virus; Screening; Vaccine

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT HEPATITIS B VACCINE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B ANTIGEN;

DIAGNOSTIC TEST; GENOTYPE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; NONHUMAN; PATHOGENESIS; REVIEW; SCREENING; TREATMENT OUTCOME; VACCINATION; VIRUS INHIBITION; VIRUS REPLICATION; COMPLICATION; DRUG EFFECTS; FEMALE; GENETICS; HEPATITIS C; HETEROZYGOTE; HISTORY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LIVER CIRRHOSIS; MASS SCREENING; NEWBORN; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PHYSIOLOGY; PREGNANCY; PREVENTIVE MEDICINE; PROCEDURES; TRENDS;

ANTIVIRAL AGENTS; CARRIER STATE; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS C; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; LIVER CIRRHOSIS; MASS SCREENING; MONITORING, PHYSIOLOGIC; PREGNANCY; PREVENTIVE MEDICINE; TREATMENT OUTCOME;

EID: 77954626837     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.05.003     Document Type: Review

References (100)

1. Blumberg B.S., Gerstley B.J., Hungerford D.A., et al. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967, 66:924-931.
2. Dane D.S., Cameron C.H., Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970, 1:695-698.
3. Almeida J.D., Rubenstein D., Stott E.J. New antigen-antibody system in Australia-antigen-positive hepatitis. Lancet 1971, 2:1225-1227.
4. Krugman S., Hoofnagle J.H., Gerety R.J., et al. Viral hepatitis, type B, DNA polymerase activity and antibody to hepatitis B core antigen. N Engl J Med 1974, 290:1331-1335.
5. Robinson W.S. DNA and DNA polymerase in the core of the Dane particle of hepatitis B. Am J Med Sci 1975, 270:151-159.
6. Galibert F., Mandart E., Fitoussi F., et al. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979, 281:646-650.
7. Gibson U.E., Heid C.A., Williams P.M. A novel method for real time quantitative RT-PCR. Genome Res 1996, 6:995-1001.
8. Gordillo R.M., Gutierrez J., Casal M. Evaluation of the COBAS TaqMan 48 real-time PCR system for quantitation of hepatitis B virus DNA. J Clin Microbiol 2005, 43:3504-3507.
9. Ranki M., Schatzl H.M., Zachoval R., et al. Quantification of hepatitis B virus DNA over a wide range from serum for studying viral replicative activity in response to treatment and in recurrent infection. Hepatology 1995, 21:1492-1499.
10. Magnius L.O., Espmark J.A. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol 1972, 109:1017-1021.
11. Magnius L.O. Characterization of a new antigen-antibody system associated with hepatitis B. Clin Exp Immuno 1975, 20:209-216.
12. Alter H.J., Seeff L.B., Kaplan P.M., et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976, 295:909-913.
13. Ohori H., Onodera S., Ishida N. Demonstration of hepatitis B e antigen (HBeAg) in association with intact Dane particles. J Gen Virol 1979, 43:423-427.
14. Cappel R., DeCuyper F., Van F. Beers, e antigen and antibody, DNA polymerase, and inhibitors of DNA polymerase in acute and chronic hepatitis. J Infect Dis 1977, 136:617-622.
15. Hindman S.H., Gravelle C.R., Murphy B.L., et al. " e" Antigen, Dane particles, and serum DNA polymerase activity in HBsAg carriers. Ann Intern Med 1976, 85:458-460.
16. Imai M., Tachibana F.C., Moritsugu Y., et al. Hepatitis B antigen-associated deoxyribonucleic acid polymerase activity and e antigen/anti-e system. Infect Immun 1976, 14:631-635.
17. Nordenfelt E., Kjellen L. Dane particles, DNA polymerase, and e-antigen in two different categories of hepatitis B antigen carriers. Intervirology 1975, 5:225-232.
18. Takahashi K., Imai M., Tsuda F., et al. Association of dane particles with e antigen in the serum of asymptomatic carriers of hepatitis B surface antigen. J Immunol 1976, 117:102-105.
19. Trepo C., Bird R.G., Zuckerman A.J. Correlations between the detection of e antigen or antibody and electron microscopic pattern of hepatitis B surface antigen (HBsAg) associated particles in the serum of HBsAg carriers. J Clin Pathol 1977, 30:216-220.
20. Werner B.G., O'Connell A.P., Summers J. Association of e antigen with Dane particle DNA in sera from asymptomatic carriers of hepatitis B surface antigen. Proc Natl Acad Sci U S A 1977, 74:2149-2151.
21. Trepo C., Vnek J., Prince A.M. Delayed hypersensitivity and Arthus reaction to purified hepatitis B surface antigen (HBsAg) in immunized chimpanzees. Clin Immunol Immunopathol 1975, 4:528-537.
22. Magnius L.O., Lindholm A., Lundin P., et al. A new antigen-antibody system. Clinical significance in long-term carriers of hepatitis B surface antigen. JAMA 1975, 231:356-359.
23. Crosnier J., Jungers P., Courouce A.M., et al. Bull Acad Natl Med 1980, 164:764-776. [in French].
24. Maupas P., Chiron J.P., Barin F., et al. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet 1981, 1:289-292.
25. Szmuness W., Stevens C.E., Harley E.J., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980, 303:833-841.
26. Rendi-Wagner P., Kundi M., Stemberger H., et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001, 19:2055-2060.
27. Zuckerman J.N. Review: hepatitis B immune globulin for prevention of hepatitis B infection. J Med Virol 2007, 79:919-921.
28. Chen D.S., Hsu N.H., Sung J.L., et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987, 257:2597-2603.
29. Beasley R.P. Rocks along the road to the control of HBV and HCC. Ann Epidemiol 2009, 19:231-234.
30. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
31. Chu C.M., Karayiannis P., Fowler M.J., et al. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985, 5:431-434.
32. Chu C.M., Liaw Y.F. Natural history differences in perinatally versus adult-acquired disease. Curr Hepat Rep 2004, 3:123-131.
33. Liaw Y.F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003, 18:246-252.
34. Chu C.M., Hung S.J., Lin J., et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004, 116:829-834.
35. Hsu Y.S., Chien R.N., Yeh C.T., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-1527.
36. Chen Y.C., Chu C.M., Yeh C.T., et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007, 1:267-273.
37. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-1192.
38. Liaw Y.F., Sheen I.S., Chen T.J., et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991, 13:627-631.
39. Yuen M.F., Wong D.K., Sablon E., et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004, 39:1694-1701.
40. Hadziyannis S.J., Lieberman H.M., Karvountzis G.G., et al. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 1983, 3:656-662.
41. Carman W.F., Jacyna M.R., Hadziyannis S., et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989, 2:588-591.
42. Karayiannis P., Fowler M.J., Lok A.S., et al. Detection of serum HBV-DNA by molecular hybridisation. Correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol 1985, 1:99-106.
43. Liaw Y.F., Tai D.I., Chu C.M., et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493-496.
44. Liaw Y.F., Tai D.I., Chu C.M., et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986, 90:263-267.
45. Chu C.M., Liaw Y.F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006, 26:142-152.
46. Mason A.L., Xu L., Guo L., et al. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998, 27:1736-1742.
47. Chisari F.V. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000, 156:1117-1132.
48. Wong D.K., Cheung A.M., O'Rourke K., et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119:312-323.
49. Lin S.M., Sheen I.S., Chien R.N., et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999, 29:971-975.
50. Who U. WHO vaccine-preventable diseases: monitoring system. Global summary. WHO/IVB/2007 2007, Available at:, Accesses December 15, 2010. http://whqlibdoc.who.int/hq/2007/WHO_IVB_2007_eng.pdf.
51. Ni Y.H., Huang L.M., Chang M.H., et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007, 132:1287-1293.
52. Kao J.H., Hsu H.M., Shau W.Y., et al. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001, 139:349-352.
53. Chen H.L., Chang C.J., Kong M.S., et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 2004, 39:58-63.
54. Namgyal P. Impact of hepatitis B immunization, Europe and worldwide. J Hepatol 2003, 39(Suppl 1):77-82.
55. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1855-1859.
56. Chang M.H., You S.L., Chen C.J., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
57. Chen C.J., Iloeje U.H., Yang H.I. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007, 11:797-816,. viii.
58. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
59. Kao J.H. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 2007, 1:415-430.
60. Chu C.M., Liaw Y.F. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005, 43:411-417.
61. Papatheodoridis G.V., Chrysanthos N., Hadziyannis E., et al. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008, 15:434-441.
62. Hui C.K., Leung N., Yuen S.T., et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007, 46:395-401.
63. Tai D.I., Lin S.M., Sheen I.S., et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009, 49:1859-1867.
64. Chen Y.C., Sheen I.S., Chu C.M., et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084-1089.
65. Tillmann H.L., Hadem J., Leifeld L., et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006, 13:256-263.
66. Kim W.R., Terrault N.A., Pedersen R.A., et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009, 137:1680-1686.
67. Lau G.K. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008, 2:152-162.
68. Samuel D., Muller R., Alexander G., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993, 329:1842-1847.
69. Fischer L., Sterneck M., Zollner B., et al. Lamivudine improves the prognosis of patients with hepatitis B after liver transplantation. Transplant Proc 2000, 32:2128-2130.
70. Gane E.J., Angus P.W., Strasser S., et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007, 132:931-937.
71. Chien R.N., Lin C.H., Liaw Y.F. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003, 38:322-327.
72. Leung N.W., Lai C.L., Chang T.T., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33:1527-1532.
73. Liaw Y.F., Chang T.T., Wu S.S., et al. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901. Hepatology 2008, 48:706A.
74. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
75. Cooksley W.G., Piratvisuth T., Lee S.D., et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003, 10:298-305.
76. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2695.
77. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
78. Dan Y.Y., Aung M.O., Lim S.G. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008, 2:284-295.
79. Liaw Y.F. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009, 51:403-410.
80. Keeffe E.B., Dieterich D.T., Han S.H., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315-1341. [quiz: 1286].
81. European Association For The Study Of The Liver EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
82. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
83. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
84. Kariv R., Leshno M., Beth-Or A., et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int 2006, 26:445-450.
85. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.
86. Lai M., Hyatt B.J., Nasser I., et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007, 47:760-767.
87. Fung J., Lai C.L., But D., et al. Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Hepatology 2007, 46:647A.
88. Gui H., Xia Q., Wang H., et al. Predictors of significant histological findings in chronic hepatitis B patients with persistently normal ALT levels. Hepatology 2007, 46:653A.
89. Nguyen M.H., Trinh H., Garcia R.T., et al. High prevalence of significant histologic disease in patients with chronic hepatitis B and normal ALT. Hepatology 2007, 46:680A.
90. Dumolard L., Gacic-Dobo M., Shapiro C.N., et al. Centers for Disease Control and Prevention (CDC). Implementation of newborn hepatitis B vaccination-worldwide, 2006. MMWR Morb Mortal Wkly Rep 2008, 57:1249-1252.
91. Lin S.Y., Chang E.T., So S.K. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology 2007, 46:1034-1040.
92. Hann H.W., Hann R.S., Maddrey W.C. Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am J Gastroenterol 2007, 102:767-772.
93. IOM Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C 2009, 250. The National Academies Press, Washington, DC. H.M. Colvin, A.E. Mitchell (Eds.).
94. Chien R.N., Liaw Y.F. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008, 22:1081-1092.
95. Buti M., Brosa M., Casado M.A., et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009, 51:640-646.
96. Liaw Y.F. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009, 14:13-22.
97. Keeffe E.B., Zeuzem S., Koff R.S., et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007, 5:890-897.
98. Werle-Lapostolle B., Bowden S., Locarnini S., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126:1750-1758.
99. Peters M., Shouval D., Bonham A., et al. Posttransplantation: future therapies. Semin Liver Dis 2000, 20(Suppl):S19-S24.
100. Wands J., Geissler M., Putlitz J., et al. Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. J Gastroenterol Hepatol 1997, 12(Suppl):S354-S369.